Historical data shows that a consistent $500 monthly investment into BioNexus Gene Lab Corp. (BGLC) starting in 2020 would have turned a total investment of $43K into $10K today. This represents a total return of -77.1% over the 6-year period, compounding through dividend reinvestment and market growth.
The Impact of Dividend Reinvestment (DRIP)
BioNexus Gene Lab Corp. does not currently pay a notable dividend. For growth-focused stocks like BGLC, dollar cost averaging relies entirely on price appreciation. Over the 6-year period, the strategy successfully captured the stock's price movements, resulting in a final portfolio value of $10K without the need for dividend reinvestment.
BGLC vs. S&P 500 (SPY) Benchmark
When comparing this dollar cost averaging strategy against a broad market index,BGLC underperformed the S&P 500 ETF (SPY). The same $500 monthly contributions into SPY would have grown to $68K, compared to BGLC's $10K.